Computational Model Underlines Need for Personalised Approach to Sepsis
Sepsis occurs when the body’s normal immune response to injury and infection goes awry, causing systemic inflammation that kills up to half of sufferers. So far, researchers have struggled to find drugs that effectively combat sepsis, so patients are mainly treated with antibiotics to fight the underlying condition.
In a new study published in PLOS Computational Biology, Chase Cockrell and Gary An of the University of Chicago employed a computational model of the human immune system to explore the challenges of attacking the molecular processes underlying sepsis. The model, developed previously to investigate systemic inflammation, simulates how immune system cells and signaling molecules behave during sepsis, as well as the effects of disrupting these processes.
The model suggested successful treatment would require drugs targeting multiple immune system processes: disrupting a single signaling process would not be sufficient. This may explain why previous attempts that employed such a strategy have not been effective. The model also indicated that a “one-size-fits-all” multi-target approach would still be inadequate, demonstrating the need for treatment to adapt, perhaps using a machine-learning algorithm, to a patient’s individual response.
Cockrell believes that his findings may be “a reality check” for those working on sepsis treatments. “It will hopefully help focus research into those areas that will actually provide a path towards effective therapy, such as high-resolution diagnostics and sampling, and realizing that there is no ‘one-size-fits-all’ answer.”
Researchers Democratize Neuroscience by Making it Easier to Share Brain Imaging DataNews
Researchers have developed a set of tools to make one critical area of big data research — that of our central nervous system — easier to share.READ MORE
H7N9 Influenza Vaccine Clinical Trials CommenceNews
Two new clinical trials testing an experimental vaccine to prevent influenza caused by an H7N9 influenza virus are now enrolling volunteers at sites across the United States. The Phase 2 studies will test different dosages of the inactivated influenza vaccine candidate as well as different vaccination schedules. The studies also will evaluate whether an adjuvant boosts the immune responses of people receiving the vaccine.
Researchers Fine-Tune Computer-Assisted Drug Repositioning Process to Treat Rare DiseasesNews
Researchers at the LSU Computational Systems Biology group have developed a sophisticated and systematic way to identify existing drugs that can be repositioned to treat a rare disease or condition.READ MORE